Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-05-31

Clinical Trial Update: Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating canakinumab (Ilaris) for urticarial vasculitis has been completed, investigating treatment responses.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ILARIS (canakinumab)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Urticaria, Vasculitis | Phase 2 | Status: COMPLETED